NCT05943496 - Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 2, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2027

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

Acalabrutinib

Given PO

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow biopsy and/or aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy and/or aspiration

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Echocardiography

Undergo ECHO

BIOLOGICAL

Obinutuzumab

Given IV

OTHER

Questionnaire Administration

Ancillary studies

BIOLOGICAL

Tafasitamab

Given IV

Trial Locations (1)

RECRUITING

OHSU Knight Cancer Institute, Portland